We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories (ABT - Free Report) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.
ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning.
Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.
Company:
Beat earnings estimates. The company posted earnings of $0.65 cents per share, beating our Zacks Consensus Estimate of $0.64. Zacks estimates excluded $0.12 from non-recurring items.
Underperformed revenue estimates. The company saw revenue figures of $5.33 billion, not meeting our estimate of $5.357 billion.
Abbott Laboratories reported that in their fourth quarter Pediatric Nutrition sales decreased by 5.4% and worldwide Adult Nutrition sales fell 1.4%, on a reported basis. However, Abbott’s PediaSure brand and other recently launched infant formula products led above-market sales growth in the United States.
Diluted GAAP EPS from continuing operations shows an outlook for full-year 2017 to be between $0.92 and $1.02 a share. This guidance includes amortization and integration expenses to the acquisition of St. Jude Medical.
Good news for investors, as Abbott Laboratories will continue to increase its quarterly dividend payment by $0.005 to $0.0265.
Here’s a graph that looks at Abbott Laboratories’ price, consensus and EPS surprise:
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories participates in the sale of health care products through their own discoveries, developments and manufacturing. The company employees 74,000 employees around the world and can be found in over 150 countries. Products in the categories of nutrition, diagnostics, diabetes care and pharmaceuticals are sold by them.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results
Abbott Laboratories (ABT - Free Report) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.
ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning.
Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.
Company:
Beat earnings estimates. The company posted earnings of $0.65 cents per share, beating our Zacks Consensus Estimate of $0.64. Zacks estimates excluded $0.12 from non-recurring items.
Underperformed revenue estimates. The company saw revenue figures of $5.33 billion, not meeting our estimate of $5.357 billion.
Abbott Laboratories reported that in their fourth quarter Pediatric Nutrition sales decreased by 5.4% and worldwide Adult Nutrition sales fell 1.4%, on a reported basis. However, Abbott’s PediaSure brand and other recently launched infant formula products led above-market sales growth in the United States.
Diluted GAAP EPS from continuing operations shows an outlook for full-year 2017 to be between $0.92 and $1.02 a share. This guidance includes amortization and integration expenses to the acquisition of St. Jude Medical.
Good news for investors, as Abbott Laboratories will continue to increase its quarterly dividend payment by $0.005 to $0.0265.
Here’s a graph that looks at Abbott Laboratories’ price, consensus and EPS surprise:
Abbott Laboratories Price, Consensus and EPS Surprise
Abbott Laboratories participates in the sale of health care products through their own discoveries, developments and manufacturing. The company employees 74,000 employees around the world and can be found in over 150 countries. Products in the categories of nutrition, diagnostics, diabetes care and pharmaceuticals are sold by them.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>